These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

544 related articles for article (PubMed ID: 11842443)

  • 1. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease.
    Lastres-Becker I; Hansen HH; Berrendero F; De Miguel R; Pérez-Rosado A; Manzanares J; Ramos JA; Fernández-Ruiz J
    Synapse; 2002 Apr; 44(1):23-35. PubMed ID: 11842443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease.
    Lastres-Becker I; de Miguel R; De Petrocellis L; Makriyannis A; Di Marzo V; Fernández-Ruiz J
    J Neurochem; 2003 Mar; 84(5):1097-109. PubMed ID: 12603833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors.
    Sagredo O; Ramos JA; Decio A; Mechoulam R; Fernández-Ruiz J
    Eur J Neurosci; 2007 Aug; 26(4):843-51. PubMed ID: 17672854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease.
    Lastres-Becker I; Fezza F; Cebeira M; Bisogno T; Ramos JA; Milone A; Fernández-Ruiz J; Di Marzo V
    Neuroreport; 2001 Jul; 12(10):2125-9. PubMed ID: 11447320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arvanil, a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of Huntington's disease.
    de Lago E; Urbani P; Ramos JA; Di Marzo V; Fernández-Ruiz J
    Brain Res; 2005 Jul; 1050(1-2):210-6. PubMed ID: 15975564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cannabinoid (CB(1)), GABA(A) and GABA(B) receptor subunit changes in the globus pallidus in Huntington's disease.
    Allen KL; Waldvogel HJ; Glass M; Faull RL
    J Chem Neuroanat; 2009 Jul; 37(4):266-81. PubMed ID: 19481011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroprotective effect of nicotine against 3-nitropropionic acid (3-NP)-induced experimental Huntington's disease in rats.
    Tariq M; Khan HA; Elfaki I; Al Deeb S; Al Moutaery K
    Brain Res Bull; 2005 Sep; 67(1-2):161-8. PubMed ID: 16140176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders.
    de Lago E; Fernández-Ruiz J; Ortega-Gutiérrez S; Cabranes A; Pryce G; Baker D; López-Rodríguez M; Ramos JA
    Eur Neuropsychopharmacol; 2006 Jan; 16(1):7-18. PubMed ID: 16006105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease.
    Dowie MJ; Bradshaw HB; Howard ML; Nicholson LF; Faull RL; Hannan AJ; Glass M
    Neuroscience; 2009 Sep; 163(1):456-65. PubMed ID: 19524019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Striatal dopamine level contributes to hydroxyl radical generation and subsequent neurodegeneration in the striatum in 3-nitropropionic acid-induced Huntington's disease in rats.
    Pandey M; Borah A; Varghese M; Barman PK; Mohanakumar KP; Usha R
    Neurochem Int; 2009 Nov; 55(6):431-7. PubMed ID: 19410615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discriminative behavioral assessment unveils remarkable reactive astrocytosis and early molecular correlates in basal ganglia of 3-nitropropionic acid subchronic treated rats.
    Cirillo G; Maggio N; Bianco MR; Vollono C; Sellitti S; Papa M
    Neurochem Int; 2010 Jan; 56(1):152-60. PubMed ID: 19799953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tiagabine, a GABA uptake inhibitor, attenuates 3-nitropropionic acid-induced alterations in various behavioral and biochemical parameters in rats.
    Dhir A; Akula KK; Kulkarni SK
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):835-43. PubMed ID: 18234412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease.
    Silverdale MA; McGuire S; McInnes A; Crossman AR; Brotchie JM
    Exp Neurol; 2001 Jun; 169(2):400-6. PubMed ID: 11358453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease.
    Segovia G; Mora F; Crossman AR; Brotchie JM
    Mov Disord; 2003 Feb; 18(2):138-49. PubMed ID: 12539206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurochemical effects of the endocannabinoid uptake inhibitor UCM707 in various rat brain regions.
    de Lago E; Ortega-Gutiérrez S; Ramos JA; López Rodríguez ML; Fernández-Ruiz J
    Life Sci; 2007 Feb; 80(10):979-88. PubMed ID: 17173937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of cannabinoid CB(1) receptors in the basal ganglia in the late akinetic phase of rats with experimental Huntington's disease.
    Lastres-Becker I; Gómez M; De Miguel R; Ramos JA; Fernández-Ruiz J
    Neurotox Res; 2002; 4(7-8):601-608. PubMed ID: 12709298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntington's disease.
    Lastres-Becker I; Berrendero F; Lucas JJ; Martín-Aparicio E; Yamamoto A; Ramos JA; Fernández-Ruiz JJ
    Brain Res; 2002 Mar; 929(2):236-42. PubMed ID: 11864629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intrastriatal serotonin 5-HT2 receptors mediate dopamine D1-induced hyperlocomotion in 6-hydroxydopamine-lesioned rats.
    Bishop C; Kamdar DP; Walker PD
    Synapse; 2003 Nov; 50(2):164-70. PubMed ID: 12923819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroprotective effect of taurine in 3-nitropropionic acid-induced experimental animal model of Huntington's disease phenotype.
    Tadros MG; Khalifa AE; Abdel-Naim AB; Arafa HM
    Pharmacol Biochem Behav; 2005 Nov; 82(3):574-82. PubMed ID: 16337998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat.
    Carta AR; Frau L; Pinna A; Pontis S; Simola N; Schintu N; Morelli M
    Synapse; 2008 Jul; 62(7):524-33. PubMed ID: 18435422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.